[go: up one dir, main page]

PE134799A1 - Derivados de carbohidrato - Google Patents

Derivados de carbohidrato

Info

Publication number
PE134799A1
PE134799A1 PE1998001123A PE00112398A PE134799A1 PE 134799 A1 PE134799 A1 PE 134799A1 PE 1998001123 A PE1998001123 A PE 1998001123A PE 00112398 A PE00112398 A PE 00112398A PE 134799 A1 PE134799 A1 PE 134799A1
Authority
PE
Peru
Prior art keywords
thrombosis
derivative
compound
carbohydrate derivatives
embol
Prior art date
Application number
PE1998001123A
Other languages
English (en)
Inventor
Adriaan Anton Van Boeckel Constant
Maria Dreef-Tromp Cornelia
Duchaussoy Philippe
Petitou Maurice
Egbertus Maria Basten Johannes
Original Assignee
Akzo Nobel Nv
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Sanofi Synthelabo filed Critical Akzo Nobel Nv
Publication of PE134799A1 publication Critical patent/PE134799A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A UN DERIVADO DE CARBOHIDRATO DE FORMULA I, RELACIONADOS CON GLICOSAMINOGLICANOS; R1 ES ALCOXI C1-C4; R2, R3 Y R4 SON ALCOXI C1-C4, ION (OSO3)-; EL CUAL COMPRENDE DE 4-6 GRUPOS SULFATOS. EL COMPUESTO I ES UN ANTICOAGULANTE A NIVEL DE LA CASCADA DE COAGULACION SIENDO INHIBIDOR SELECTIVO DEL ANTIFACTOR ACTIVADO Xa (ANTI-Xa), QUE TIENEN ACTIVIDAD ANTITROMBOTICA Y PUEDE SER UTIL PARA TRATAR O PREVENIR TROMBOSIS VENOSA PROFUNDA, EMBOLISMO PULMONAR, TROMBOFLEBITIS, OCLUSION ARTERIAL POR TROMBOSIS O EMBOLISMO Y PARA INHIBIR LA PROLIFERACION DE CELULAS DEL MUSCULO LISO Y PARA EL TRATAMIENTO DE ANGIOGENESIS, CANCER E INFECCIONES POR RETROVIRUS COMO VIH. EL COMPUESTO DERIVADO MUESTRA MENOS EFECTOS SECUNDARIOS COMO RIESGO DE SANGRADO, TROMBOCITOPENIA INDUCIDA POR HEPARINA
PE1998001123A 1997-11-19 1998-11-18 Derivados de carbohidrato PE134799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97203613 1997-11-19

Publications (1)

Publication Number Publication Date
PE134799A1 true PE134799A1 (es) 2000-01-07

Family

ID=8228942

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001123A PE134799A1 (es) 1997-11-19 1998-11-18 Derivados de carbohidrato

Country Status (33)

Country Link
US (1) US6174863B1 (es)
EP (1) EP1032579B1 (es)
JP (1) JP4364959B2 (es)
KR (1) KR100518497B1 (es)
CN (1) CN1177855C (es)
AR (1) AR017640A1 (es)
AT (1) ATE239030T1 (es)
AU (1) AU746959B2 (es)
BR (1) BRPI9804699B1 (es)
CA (1) CA2253113C (es)
CO (1) CO4990974A1 (es)
CZ (1) CZ293639B6 (es)
DE (1) DE69814140T2 (es)
DK (1) DK1032579T3 (es)
EE (1) EE04348B1 (es)
ES (1) ES2198081T3 (es)
HU (1) HU226685B1 (es)
ID (1) ID21287A (es)
IL (1) IL126893A (es)
IS (1) IS2527B (es)
NO (1) NO310723B1 (es)
NZ (1) NZ332834A (es)
PE (1) PE134799A1 (es)
PL (1) PL188229B1 (es)
PT (1) PT1032579E (es)
RU (1) RU2210573C2 (es)
SG (1) SG72889A1 (es)
SK (1) SK284134B6 (es)
TR (1) TR199802372A2 (es)
TW (1) TW448180B (es)
UA (1) UA49089C2 (es)
WO (1) WO1999025720A1 (es)
ZA (1) ZA9810559B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI289566B (en) * 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
CA2435637A1 (en) * 2001-01-23 2002-08-01 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
HUE025683T2 (hu) 2002-12-03 2016-04-28 Pharmacyclics Llc VIIA faktor inhibitor 2-(2-hidroxi-bifenil-3-il)-1H-benzoimidazol-5-karboxamidin-származékok
CN1317287C (zh) * 2003-04-18 2007-05-23 山东大学 一种多硫酸寡糖及其制备方法
TWI426080B (zh) * 2004-03-04 2014-02-11 Progen Pharmaceuticals Ltd 硫酸化寡醣衍生物
JP2011522805A (ja) 2008-05-30 2011-08-04 モメンタ ファーマシューティカルズ インコーポレイテッド 糖構造ならびにそのような構造を作製および使用する方法
CA2735983A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
ES2939741T3 (es) * 2009-07-31 2023-04-26 Reliable Biopharmaceutical Llc Proceso para preparar fondaparinux sódico y productos intermedios útiles en la síntesis del mismo
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
ES2560467T3 (es) * 2011-06-17 2016-02-19 Carbomimetics Pentasacáridos sintéticos que tienen vida media corta y alta actividad
EP2578594A1 (en) 2011-10-04 2013-04-10 Sanofi Process of preparation of L-iduronic acid comprising a decarboxylation/intramolecular cyclisation tandem reaction
US9873712B2 (en) 2014-10-03 2018-01-23 Amphastar Pharmaceuticals, Inc. Method of purifying idraparinux sodium
CN109134554B (zh) * 2017-06-15 2021-09-28 南京正大天晴制药有限公司 抗凝血的五糖类化合物及其制备方法和医药用途
CN109134553B (zh) * 2017-06-15 2021-09-28 南京正大天晴制药有限公司 抗凝血的五糖类化合物及其制备方法和医药用途
CN109134555B (zh) * 2017-06-15 2021-09-28 南京正大天晴制药有限公司 抗凝血的五糖类化合物及其制备方法和医药用途
WO2021043631A1 (en) 2019-09-02 2021-03-11 Hepoligo Solutions Aps Intermediates useful for preparing iduronic acid containing di- and polysaccharides
WO2021211441A1 (en) * 2020-04-13 2021-10-21 The Board Of Regents Of The University Of Oklahoma Modified sugar polymers with low anticoagulant activity and therapeutic activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2564468B1 (fr) * 1984-05-16 1994-12-23 Choay Sa Nouveaux oligosaccharides, leur preparation par voie de synthese et leurs applications biologiques
EP0300099A1 (en) * 1987-07-20 1989-01-25 Akzo N.V. New pentasaccharides
DE69100275T2 (de) * 1990-04-23 1993-12-02 Akzo Nv Eine Trisaccharideinheit enthaltende Kohlenhydratderivate.
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
EE04348B1 (et) 2004-08-16
IS2527B (is) 2009-07-15
HU9802663D0 (en) 1999-01-28
AU9324298A (en) 1999-06-17
CO4990974A1 (es) 2000-12-26
CA2253113C (en) 2008-06-17
JPH11217394A (ja) 1999-08-10
WO1999025720A1 (en) 1999-05-27
IS5485A (is) 2000-05-09
JP4364959B2 (ja) 2009-11-18
ID21287A (id) 1999-05-20
SG72889A1 (en) 2000-05-23
TW448180B (en) 2001-08-01
UA49089C2 (uk) 2002-09-16
KR19990045312A (ko) 1999-06-25
RU2210573C2 (ru) 2003-08-20
BR9804699A (pt) 2000-12-26
ATE239030T1 (de) 2003-05-15
HUP9802663A2 (hu) 1999-06-28
HUP9802663A3 (en) 2000-04-28
TR199802372A2 (xx) 1999-06-21
HU226685B1 (en) 2009-06-29
IL126893A (en) 2003-05-29
CA2253113A1 (en) 1999-05-19
CN1177855C (zh) 2004-12-01
IL126893A0 (en) 1999-09-22
NO985365D0 (no) 1998-11-18
DK1032579T3 (da) 2003-08-25
EP1032579B1 (en) 2003-05-02
EP1032579A1 (en) 2000-09-06
CZ376198A3 (cs) 1999-06-16
US6174863B1 (en) 2001-01-16
SK7362000A3 (en) 2000-10-09
AU746959B2 (en) 2002-05-09
KR100518497B1 (ko) 2005-12-16
PL329789A1 (en) 1999-05-24
DE69814140D1 (de) 2003-06-05
EE200000301A (et) 2001-12-17
NO985365L (no) 1999-05-20
AR017640A1 (es) 2001-09-12
HK1028406A1 (en) 2001-02-16
PL188229B1 (pl) 2004-12-31
NZ332834A (en) 2000-01-28
ZA9810559B (en) 1999-05-15
DE69814140T2 (de) 2004-04-08
CZ293639B6 (cs) 2004-06-16
PT1032579E (pt) 2003-08-29
SK284134B6 (sk) 2004-09-08
NO310723B1 (no) 2001-08-20
CN1222524A (zh) 1999-07-14
BRPI9804699B1 (pt) 2016-07-12
ES2198081T3 (es) 2004-01-16

Similar Documents

Publication Publication Date Title
PE134799A1 (es) Derivados de carbohidrato
Massonnet-Castel et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation
IT1282994B1 (it) Derivati del polisaccaride k5 aventi elevata attivita' anticoagulante
AU2002239841A1 (en) Proteoglycan compositions for treatment of inflammatory conditions
PL357209A1 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
BR0117124A (pt) Derivados de glicosaminoglicanos parcialmente dessulfatados como inibidores da heparanase, dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante
Fejgin et al. Low molecular weight heparins and their use in obstetrics and gynecology
ATE178212T1 (de) Sulfatierte polysaccharide mit antiinflammatorischer aktivität
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
PE20040507A1 (es) Mezclas de polisacaridos derivados de heparina, su preparacion y las composiciones farmaceuticas que las contienen
DK0979089T3 (da) Fremgangsmåder til anvendelse af makrocykliske lacton-forbindelser som multilægemiddel-resistens-reverterende midler i tumor og andre celler
Ontachi et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm
BR9905820A (pt) Composições de heparinas de peso molecular muito baixo
EP0536363B1 (en) Novel heparin derivatives and process for the preparation thereof
EA200100965A1 (ru) Синергизм между низкомолекулярным гепарином и ингибиторами агрегации тромбоцитов, обеспечивающий комбинированную терапию для профилактики и лечения различных тромбоэмболических нарушений
ES2072424T3 (es) Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.
Khoshimov et al. The effect of Sulphated cellulose on System of Haemostasis
EA200100966A1 (ru) ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
NZ533856A (en) Sulphated glycosaminoglycans with an anticoagulant activity of 100 BP units/mg or less for prophylactic priming or curative treatment of the cervix and myometrium during labour
US6828307B1 (en) Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity
SE9303612D0 (sv) New use
ES2164464T3 (es) Tratamiento de aguas residuales en el fosfatado.
Mukherjee et al. The role of low-molecular–weight heparin in cardiovascular diseases
ES2059204T3 (es) Derivados del acido hidroxamico inhibidores de lipoxigenasa.
ES2108266T3 (es) Derivados de fenil sustituido cicloalquil hidroxiureas que inhiben la lipoxigenasa.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term